Welcome to our dedicated page for Clene news (Ticker: CLNN), a resource for investors and traders seeking the latest updates and insights on Clene stock.
Clene Inc. reports developments as a late clinical-stage biopharmaceutical company developing clean-surfaced nanotechnology therapeutics for neurodegenerative diseases. Through Clene Nanomedicine Inc., the company focuses on improving mitochondrial health and protecting neuronal function in amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease.
Recurring news centers on CNM-Au8®, an investigational nanocrystal suspension designed to target mitochondrial function and the NAD pathway while reducing oxidative stress. Company updates include ALS biomarker and expanded-access data, FDA meeting and regulatory communications, operating and financial results, registered direct financing activity, shareholder communications, voting matters and investor-conference presentations.
Clene Inc. (Nasdaq: CLNN) has received a positive opinion from the European Medicines Agency for Orphan Drug Designation for CNM-Au8® aimed at treating amyotrophic lateral sclerosis (ALS). This designation, granted for serious conditions affecting fewer than 5 in 10,000 individuals, will provide Clene with regulatory benefits, including reduced fees and market exclusivity. The decision was based on data from the Phase 2 RESCUE-ALS trial, showing a statistically significant survival benefit. The company plans to expedite CNM-Au8's availability to ALS patients.
Clene Inc. (Nasdaq: CLNN) has reported promising results from its RESCUE-ALS trial, showing that patients treated with CNM-Au8 experienced significantly improved survival rates compared to those receiving a placebo. The trial indicated a 70% reduction in the risk of death for the CNM-Au8 group, based on Kaplan-Meier survival analysis (HR=0.301, p=0.0143). The treatment was also well-tolerated with no major safety issues noted. Clene anticipates releasing further data from the larger HEALEY ALS Platform Trial, aiming to confirm and expand on these promising findings.
Clene (NASDAQ: CLNN) announced that President and CEO Rob Etherington will join a virtual panel on ALS treatments, hosted by Maxim Group on June 28 at 11 a.m. EDT. The discussion will address the urgent need for new therapies for amyotrophic lateral sclerosis (ALS), as current options are limited. Clene's lead candidate, CNM-Au8®, is in late-stage trials, with topline data expected in Q3 from a Phase 2/3 study. This drug aims to restore neuronal health with gold nanocrystals, enhancing energy production and offering neuroprotection.
Clene Inc. (NASDAQ: CLNN) has announced its support for Lou Gehrig Day, marking the occasion by broadcasting a message on the Nasdaq MarketSite tower in Times Square. This initiative enhances awareness for ALS, a disease that Gehrig famously battled. Former Yankees outfielder Chris Dickerson will feature in the message, emphasizing commitment to ALS research and treatment. Clene is focused on new therapies and anticipates topline results from its Phase 2/3 clinical trial for its lead drug candidate, CNM-Au8, in the upcoming quarter.
Clene presented new interim survival data from its Phase 2 RESCUE-ALS study, showing that early treatment with CNM-Au8 reduced mortality risk by 62% compared to delayed treatment (HR 0.38; p = 0.06) and by 64% against the ENCALS predicted median survival (HR 0.36; p=0.008). The data suggest significant neuroprotection and improved quality of life for ALS patients. The ongoing study has been extended indefinitely, highlighting CNM-Au8’s potential as a disease-modifying treatment for ALS.
Clene Inc. (NASDAQ: CLNN) has secured a $3 million loan from Maryland’s Neighborhood BusinessWorks program to facilitate capital equipment purchases for a new 75,000-square-foot manufacturing facility in Elkton, Maryland. This facility will support the production of CNM-Au8®, Clene's lead drug candidate aimed at treating ALS. This non-dilutive funding aims to bolster Clene’s manufacturing capabilities in anticipation of potential commercialization, with topline data expected from a Phase 2/3 registrational study in Q3 2022.
Clene Inc. (NASDAQ: CLNN) will participate in several upcoming investor conferences, showcasing its commitment to revolutionizing the treatment of neurodegenerative diseases. The company will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 2 p.m. ET, followed by participation in the Benchmark Healthcare House Call Virtual 1x1 Conference on June 2, 2022, and the JMP Securities Life Sciences Conference on June 15, 2022, also at 2 p.m. ET. Clene focuses on addressing energetic failure, a key factor in many neurological conditions.
Clene Inc. (Nasdaq: CLNN) reported its Q1 2022 results, revealing cash, cash equivalents, and marketable securities of $36.6 million. The company anticipates data readouts for its lead asset, CNM-Au8®, for ALS and MS in Q3 2022. Key results from the RESCUE-ALS trial showed a 70% survival benefit for patients in an open-label extension. Operating expenses rose, with R&D at $8.6 million, while net loss improved to $13.4 million, down from $39.8 million year-over-year. Clene expects funding will last into Q2 2023.
Clene Inc. (NASDAQ: CLNN) has announced promising new data from the open-label extension of its RESCUE-ALS study, revealing a significant 70% survival benefit for ALS patients treated with CNM-Au8®. The interim analysis showed a hazard ratio of 0.3 (p=0.006), indicating a lower mortality risk compared to the ENCALS prediction model. The Phase 2 study also highlighted benefits in slowing disease progression and enhancing life quality. CEO Rob Etherington expresses optimism for future trials and the potential to change treatment paradigms for ALS.
Clene Inc. (NASDAQ: CLNN) reported promising interim results from the RESCUE-ALS trial at the 2022 MDA Clinical & Scientific Conference. The trial indicated a 70% decreased risk of death for participants who entered the long-term open-label extension compared to predictions from the ENCALS risk model. The CNM-Au8 treatment showed significant benefits in slowing ALS disease progression, with improvements in quality of life metrics. Clene aims to validate these findings during ongoing larger clinical studies.